156 related articles for article (PubMed ID: 19749798)
21. Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.
Zhang L; Wang H; Li W; Zhong J; Yu R; Huang X; Wang H; Tan Z; Wang J; Zhang Y
Oncotarget; 2017 Jan; 8(2):3289-3303. PubMed ID: 27924057
[TBL] [Abstract][Full Text] [Related]
22. A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway.
Hosaka S; Horiuchi K; Yoda M; Nakayama R; Tohmonda T; Susa M; Nakamura M; Chiba K; Toyama Y; Morioka H
J Orthop Res; 2012 Sep; 30(9):1493-8. PubMed ID: 22359392
[TBL] [Abstract][Full Text] [Related]
23. Pazopanib: Clinical development of a potent anti-angiogenic drug.
Schutz FA; Choueiri TK; Sternberg CN
Crit Rev Oncol Hematol; 2011 Mar; 77(3):163-71. PubMed ID: 20456972
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.
Liu L; Huang P; Wang Z; Chen N; Tang C; Lin Z; Peng P
BMC Cancer; 2016 Oct; 16(1):813. PubMed ID: 27756261
[TBL] [Abstract][Full Text] [Related]
25. A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.
Perry J; Ghazaly E; Kitromilidou C; McGrowder EH; Joel S; Powles T
Mol Cancer Ther; 2010 Dec; 9(12):3322-9. PubMed ID: 20889729
[TBL] [Abstract][Full Text] [Related]
26. Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors.
Melichar B; Studentová H; Zezulová M
J BUON; 2011; 16(2):203-9. PubMed ID: 21766486
[TBL] [Abstract][Full Text] [Related]
27. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.
Kasper B; Hohenberger P
Future Oncol; 2011 Dec; 7(12):1373-83. PubMed ID: 22112314
[TBL] [Abstract][Full Text] [Related]
28. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells.
Kurebayashi J; Okubo S; Yamamoto Y; Ikeda M; Tanaka K; Otsuki T; Sonoo H
Cancer Chemother Pharmacol; 2006 Oct; 58(4):460-70. PubMed ID: 16435154
[TBL] [Abstract][Full Text] [Related]
29. Beta-hydroxyisovalerylshikonin and cisplatin act synergistically to inhibit growth and to induce apoptosis of human lung cancer DMS114 cells via a tyrosine kinase-dependent pathway.
Xu Y; Kajimoto S; Nakajo S; Nakaya K
Oncology; 2004; 66(1):67-75. PubMed ID: 15031601
[TBL] [Abstract][Full Text] [Related]
30. Pazopanib: therapeutic developments.
Limvorasak S; Posadas EM
Expert Opin Pharmacother; 2009 Dec; 10(18):3091-102. PubMed ID: 19954277
[TBL] [Abstract][Full Text] [Related]
31. Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.
LaPlant KD; Louzon PD
Ann Pharmacother; 2010 Jun; 44(6):1054-60. PubMed ID: 20407031
[TBL] [Abstract][Full Text] [Related]
32. Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.
Sleebs BE; Czabotar PE; Fairbrother WJ; Fairlie WD; Flygare JA; Huang DC; Kersten WJ; Koehler MF; Lessene G; Lowes K; Parisot JP; Smith BJ; Smith ML; Souers AJ; Street IP; Yang H; Baell JB
J Med Chem; 2011 Mar; 54(6):1914-26. PubMed ID: 21366295
[TBL] [Abstract][Full Text] [Related]
33. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.
Sloan B; Scheinfeld NS
Curr Opin Investig Drugs; 2008 Dec; 9(12):1324-35. PubMed ID: 19037839
[TBL] [Abstract][Full Text] [Related]
34. In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells.
Shablak A; Gilham DE; Hawkins RE; Elkord E
Expert Opin Pharmacother; 2014 Aug; 15(11):1489-99. PubMed ID: 24890457
[TBL] [Abstract][Full Text] [Related]
35. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
Podar K; Tonon G; Sattler M; Tai YT; Legouill S; Yasui H; Ishitsuka K; Kumar S; Kumar R; Pandite LN; Hideshima T; Chauhan D; Anderson KC
Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19478-83. PubMed ID: 17164332
[TBL] [Abstract][Full Text] [Related]
36. TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.
Zizzari IG; Napoletano C; Botticelli A; Caponnetto S; Calabrò F; Gelibter A; Rughetti A; Ruscito I; Rahimi H; Rossi E; Schinzari G; Marchetti P; Nuti M
Cancer Immunol Res; 2018 Jun; 6(6):711-722. PubMed ID: 29700053
[TBL] [Abstract][Full Text] [Related]
37. Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo.
Booth L; Albers T; Roberts JL; Tavallai M; Poklepovic A; Lebedyeva IO; Dent P
Oncotarget; 2016 Jun; 7(26):40398-40417. PubMed ID: 27259258
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of novel pazopanib derivatives as antitumor agents.
Qi H; Chen L; Liu B; Wang X; Long L; Liu D
Bioorg Med Chem Lett; 2014 Feb; 24(4):1108-10. PubMed ID: 24456902
[TBL] [Abstract][Full Text] [Related]
39. Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer.
Ball DW; Jin N; Xue P; Bhan S; Ahmed SR; Rosen DM; Schayowitz A; Clark DP; Nelkin BD
Oncol Rep; 2015 Nov; 34(5):2319-24. PubMed ID: 26324075
[TBL] [Abstract][Full Text] [Related]
40. Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells.
Kacan T; Altun A; Altun GG; Kacan SB; Sarac B; Seker MM; Bahceci A; Babacan N
Asian Pac J Cancer Prev; 2014; 15(7):3185-9. PubMed ID: 24815468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
